2. Search Result
Search Result
Results for "

hypoglycemia

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

2

Biochemical Assay Reagents

8

Peptides

1

Inhibitory Antibodies

4

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0264
    Exendin(9-39) amide
    30+ Cited Publications

    Avexitide

    		 GLP Receptor Metabolic Disease
    Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .
    Exendin(9-39) amide
  • HY-D0227
    THAM
    1 Publications Verification

    Tris; Tris(hydroxymethyl)aminomethane

    		 Biochemical Assay Reagents Metabolic Disease
    THAM (Tris) is a low-toxicity amino alcohol buffer, a specific CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications .
    THAM
  • HY-121965
    β-D-Glucose

    		Biochemical Assay Reagents Endogenous Metabolite Others
    β-D-Glucose, also known as glucose, is a monosaccharide, the most important carbohydrate in biological systems, the main energy source of cells, and plays a key role in various metabolic processes. β-D-Glucose has unique chemical properties that make it an abundant component in plant and animal tissues and is readily metabolized by organisms to produce cellular energy. It is commonly used to improve hypoglycemia and dehydration, and as a sweetener and preservative in food and beverage production.
    β-D-Glucose
  • HY-108743
    Insulin degludec

    		Insulin Receptor Endocrinology
    Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .
    Insulin degludec
  • HY-P3469A
    Dasiglucagon acetate

    		GCGR Metabolic Disease
    Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research .
    Dasiglucagon acetate
  • HY-10581
    Gatifloxacin
    4 Publications Verification

    AM-1155; BMS-206584; PD135432

    		 Bacterial Topoisomerase Antibiotic Infection Neurological Disease Cancer
    Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic that can cross the blood-brain barrier, with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin
  • HY-P10957
    Imapextide

    MBX 1416

    		 GLP Receptor Metabolic Disease
    Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .
    Imapextide
  • HY-108615
    CP-316819

    GPi 819

    		 Phosphorylase Cardiovascular Disease Neurological Disease Metabolic Disease
    CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes .
    CP-316819
  • HY-15675
    AZD1656

    		Glucokinase Metabolic Disease
    AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research .
    AZD1656
  • HY-10581A
    Gatifloxacin hydrochloride
    4 Publications Verification

    AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride

    		 Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin hydrochloride
  • HY-D0227J
    THAM hydrochloride (≥99%, for cell culture)
    1 Publications Verification

    Tris HCl (≥99%, for cell culture); Tris hydrochloride (≥99%, for cell culture)

    		 Biochemical Assay Reagents Metabolic Disease
    THAM hydrochloride (≥99%, for cell culture) is a low-toxicity amino alcohol buffer, a specific CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM hydrochloride (≥99%, for cell culture) binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM hydrochloride (≥99%, for cell culture) may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM hydrochloride (≥99%, for cell culture) removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM hydrochloride (≥99%, for cell culture) can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM hydrochloride (≥99%, for cell culture) is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications .
    THAM hydrochloride (≥99%, for cell culture)
  • HY-P0264A
    Exendin(9-39) amide acetate
    30+ Cited Publications

    Avexitide acetate

    		 GLP Receptor Metabolic Disease
    Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .
    Exendin(9-39) amide acetate
  • HY-106577
    Cibenzoline

    Cifenline; Ro 22-7796

    		 Potassium Channel Cardiovascular Disease Metabolic Disease
    Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
    Cibenzoline
  • HY-114191B
    SSTR5 antagonist 2 hydrochloride

    		Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .
    SSTR5 antagonist 2 hydrochloride
  • HY-N3015
    Bruceine E

    		Others Metabolic Disease
    Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .
    Bruceine E
  • HY-D0227B
    THAM acetate
    1 Publications Verification

    Tris acetate; Tris(hydroxymethyl)aminomethane acetate

    		 Biochemical Assay Reagents Metabolic Disease
    THAM acetate is a low-toxicity amino alcohol buffer, a CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM acetate binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM acetate may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM acetate removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM acetate can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM acetate is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications .
    THAM acetate
  • HY-P3469
    Dasiglucagon

    		GCGR Metabolic Disease
    Dasiglucagon is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research .
    Dasiglucagon
  • HY-179141
    α-Amylase/α-Glucosidase-IN-23

    		Amylases Glycosidase Metabolic Disease
    α-Amylase/α-Glucosidase-IN-23 (Compound 5e) is a α-Amylase/α-Glucosidase inhibitor with IC50 values of 73.68 nM for α-glucosidase and 146.18 nM for α-amylase. α-Amylase/α-Glucosidase-IN-23 can be used in the research of hypoglycemia .
    α-Amylase/α-Glucosidase-IN-23
  • HY-178192
    mTORC1-IN-3

    		mTOR Autophagy Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    mTORC1-IN-3 is a potent and selective mTORC1 inhibitor with an IC50 of 26.38 μM . mTORC1-IN-3 selectively inhibits the phosphorylation of mTORC1 substrates and does not without affect the phosphorylation of mTORC2 substrate. mTORC1-IN-3 can reduce cellular lipid accumulation and induce autophagy. mTORC1-IN-3 can be used for the researches of cancer, immunology, metabolic and neurological disease, such as diabetes and Alzheimer’s disease .
    mTORC1-IN-3
  • HY-P3056
    GHRF, ovine

    		GHSR Endocrinology
    GHRF, ovine is a growth hormone-releasing factor. GHRF is a specific mediator for the effects of hypoglycemia upon the release of pituitary growth hormone (GH) .
    GHRF, ovine
  • HY-164040
    Zavolosotine

    		Somatostatin Receptor Metabolic Disease
    Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC50 <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .
    Zavolosotine
  • HY-120493A
    AM-6226

    		Free Fatty Acid Receptor Metabolic Disease
    AM-6226 is a potent and orally active G protein coupled receptor 40 (GPR40) full agonist with an EC50 of 0.12 μM. AM-6226 can activate the GPR40 receptors on pancreatic β cells and enteroendocrine L cells, promote insulin secretion in a glucose-dependent manner and also increase the release of incretin hormones (GLP-1, GIP), thereby avoiding the risk of hypoglycemia. AM-6226 can be used for the research of metabolic disease, such as diabetes .
    AM-6226
  • HY-10581C
    Gatifloxacin sesquihydrate

    AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate

    		 Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin sesquihydrate
  • HY-P991291
    XOMA 129

    		Insulin Receptor Endocrinology
    XOMA 129 is a human monoclonal antibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .
    XOMA 129
  • HY-115014
    Cibenzoline succinate

    Cifenline succinate; Ro 22-7796 succinate

    		 Potassium Channel Cardiovascular Disease Metabolic Disease
    Cibenzoline succinate (Cifenline succinate) is the succinate form of Cibenzoline (HY-106577). Cibenzoline succinate is an inhibitor for ATP-sensitive potassium (KATP) channel by affecting the pore-forming Kir6.2 subunit with IC50 of 22.2 µM. Cibenzoline succinate affects insulin secretion and exhibits antiarrhythmic and antidiabetic activities .
    Cibenzoline succinate
  • HY-123171
    ASP8497

    		Dipeptidyl Peptidase Metabolic Disease
    ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .
    ASP8497
  • HY-159496
    Dyrk1A-IN-10

    		DYRK Metabolic Disease
    Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .
    Dyrk1A-IN-10
  • HY-125316
    AMG-151

    ARRY-403

    		 Endogenous Metabolite Metabolic Disease
    AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes .
    AMG-151
  • HY-106577R
    Cibenzoline (Standard)

    Cifenline (Standard); Ro 22-7796 (Standard)

    		 Reference Standards Potassium Channel Cardiovascular Disease Metabolic Disease
    Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
    Cibenzoline (Standard)
  • HY-106577S
    Cibenzoline-d4

    Cifenline-d4; Ro 22-7796-d4

    		 Isotope-Labeled Compounds Potassium Channel Cardiovascular Disease Metabolic Disease
    Cibenzoline-d4 (Cifenline-d4) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
    Cibenzoline-d4
  • HY-114191
    SSTR5 antagonist 2

    		Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .
    SSTR5 antagonist 2
  • HY-114191A
    SSTR5 antagonist 2 TFA

    		Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .
    SSTR5 antagonist 2 TFA
  • HY-P11275
    TC4

    		GLP Receptor GCGR Neuropeptide Y Receptor Metabolic Disease
    TC4 is a highly balanced single-molecule quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.95, 31, 81, and 1100 nM respectively. TC4 exhibits extremely strong signal bias on GLP-1R and has very low recruitment efficacy for β-inhibitor protein 2 (βArr2) and this strong cAMP preference is believed to maximize metabolic benefits (such as weight loss and hypoglycemia) while possibly minimizing side effects mediated by β-inhibitor protein recruitment (such as receptor desensitization). TC4 can be used for research on obesity and diabetes .
    TC4
  • HY-10581B
    Gatifloxacin mesylate

    AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate

    		 Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin mesylate
  • HY-10581AR
    Gatifloxacin hydrochloride (Standard)

    AM-1155 hydrochloride (Standard); BMS-206584 hydrochloride (Standard); PD135432 hydrochloride (Standard)

    		 Reference Standards Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (hydrochloride) (Standard) is the analytical standard of Gatifloxacin (hydrochloride). This product is intended for research and analytical applications. Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin hydrochloride (Standard)
  • HY-10581R
    Gatifloxacin (Standard)

    AM-1155 (Standard); BMS-206584 (Standard); PD135432 (Standard)

    		 Reference Standards Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (Standard) is the analytical standard of Gatifloxacin. This product is intended for research and analytical applications. Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin (Standard)
  • HY-10581CR
    Gatifloxacin sesquihydrate (Standard)

    AM-1155 sesquihydrate (Standard); BMS-206584 sesquihydrate (Standard); PD135432 sesquihydrate (Standard)

    		 Reference Standards Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin (sesquihydrate) (Standard) is the analytical standard of Gatifloxacin (sesquihydrate). This product is intended for research and analytical applications. Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis?in vivo.
    Gatifloxacin sesquihydrate (Standard)
  • HY-127003
    Neoambrosin

    		PPAR TRP Channel Metabolic Disease Inflammation/Immunology Cancer
    Neoambrosin is a sesquiterpene lactone. Neoambrosin acts as a partial agonist of PPARγ and TRPA1 receptors, with no carbonic anhydrase inhibitory activity. Neoambrosin can be used in research on hypoglycemia, analgesia, anti-inflammation and anticancer effects .
    Neoambrosin
  • HY-108615R
    CP-316819 (Standard)

    GPi 819 (Standard)

    		 Phosphorylase Reference Standards Cardiovascular Disease Neurological Disease Metabolic Disease
    CP-316819 (GPi 819) Standard is the analytical standard of CP-316819 (HY-108615). This product is intended for research and analytical applications. CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes.
    CP-316819 (Standard)
  • HY-182386
    Triflocin

    		NKCC Metabolic Disease Endocrinology
    Triflocin is an orally active diuretic and Na +-K +-2Cl − cotransporter inhibitor with an IC50 of 3×10 -5 M. Triflocin inhibits the outward basolateral electrogenic Na-(HCO3) n>1 cotransport in the proximal tubule. Triflocin has no tendency to induce hyperglycemia, and its blood glucose-elevating effect is extremely weak, such that an increase in blood glucose levels can only be detected under special conditions such as glucose loading. Triflocin is more prone to induce hypoglycemia .
    Triflocin
  • HY-106577S1
    Cibenzoline-d5

    Cifenline-d5; Ro 22-7796-d5

    		 Isotope-Labeled Compounds Cardiovascular Disease Metabolic Disease
    Cibenzoline-d5 (Cifenline-d5) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
    Cibenzoline-d5
  • HY-N17294
    Dendromoniliside D

    		Amylases Cancer
    Dendromoniliside D is a sesquiterpene glycoside. Dendromoniliside D can be isolated from D. nobile. Dendromoniliside D inhibits α-amylase. Dendromoniliside D can be used in the research of liver cancer, lung cancer, and breast cancer .
    Dendromoniliside D
  • HY-120493
    (rel)-AM-6226

    		Free Fatty Acid Receptor Metabolic Disease
    (rel)-AM-6226 is the relative stereoisomer of AM-6226 (HY-120493A). AM-6226 is a potent, orally active full agonist of G protein-coupled receptor 40 (GPR40) with an EC50 value of 0.12 μM. AM-6226 activates GPR40 receptors on pancreatic β-cells and enteroendocrine L-cells, promotes insulin secretion in a glucose-dependent manner, and increases the release of incretin hormones (GLP-1, GIP), thus avoiding the risk of hypoglycemia. AM-6226 can be used in the research of metabolic diseases such as diabetes .
    (rel)-AM-6226
  • HY-W093416
    3,3-Azo-1-butanol

    		TRP Channel Metabolic Disease
    3,3-Azo-1-butanol is an orally active hypoglycemic agent. 3,3-Azo-1-butanol increases liver weight and induces fat infiltration .
    3,3-Azo-1-butanol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: